Mechanistic description
Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF and ultimately into peripheral blood via degraded BBB transport mechanisms. Early BBB disruption increases permeability of neurofilament-derived peptides into circulation, causing disproportionate plasma NfL elevation relative to CSF levels. This makes plasma NfL a sensitive indicator of BBB permeability-augmented neurodegeneration, enabling peripheral blood-based disease progression monitoring. Multiple FDA-cleared platforms (Simoa, Elecsys, Lumipulse) provide validated detection.
Evidence for (9)
Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts.
Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank.
Blood-Brain Barrier: From Physiology to Disease and Back.
Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.
Development, maintenance and disruption of the blood-brain barrier.
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.
Blood-brain barrier biomarkers.
Proteolytic cleavage of damaged neurofilaments releases NfL into the extracellular space
Evidence against (2)
NfL elevation is non-specific to neurodegeneration (also elevated in trauma, stroke)
Neurofilament light chain as a biomarker in neurological disorders.
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 8 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.